OmerosOMER
OMER
About: Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Employees: 202
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
182% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 11
164% more capital invested
Capital invested by funds: $99.3M [Q3] → $262M (+$163M) [Q4]
92% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 26
19% more funds holding
Funds holding: 108 [Q3] → 128 (+20) [Q4]
2.64% more ownership
Funds ownership: 43.19% [Q3] → 45.83% (+2.64%) [Q4]
9% more call options, than puts
Call options by funds: $12.6M | Put options by funds: $11.6M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$36
431%
upside
Avg. target
$36
431%
upside
High target
$36
431%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 21% 1-year accuracy 74 / 353 met price target | 431%upside $36 | Buy Maintained | 11 Apr 2025 |
Financial journalist opinion
Based on 8 articles about OMER published over the past 30 days
Positive
Benzinga
1 week ago
Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight
Omeros Corporation OMER on Thursday established the Omeros Oncology Clinical Steering Committee to advance Omeros' OncotoX biologics program focused on acute myeloid leukemia (AML).
Neutral
Business Wire
1 week ago
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros' OncotoX biologics program focused on acute myeloid leukemia (AML). AML is the most fatal form of leukemia and accounts for approximately 80 percent of acute leukemias in adults and one-third of all cancers affecting the blood/bone marrow, representing a high unmet need. Omeros' OncotoX program for AML consists of proprietary targeted.
Neutral
Business Wire
1 week ago
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the first public presentation of its proprietary Targeted Complement Activating TherapyTM (T-CATTM) platform will occur at the European Congress on Infectious Diseases 2025 in Rome, Italy on Monday, April 14. The plenum presentation, titled Augmenting cytotoxicity of pathogen-specific antibodies which initiate complement activation independent of the classical pathway, will be delivered by Prof. Wilhelm Schwaeble,.
Neutral
Seeking Alpha
2 weeks ago
Omeros Corporation (OMER) Q4 2024 Earnings Call Transcript
Omeros Corporation (NASDAQ:OMER ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants Jennifer Williams - Investor and Media relations, Cook Williams Communications, Inc. Gregory Demopulos - Chairman & CEO David Borges - Chief Accounting Officer Catherine Melfi - Chief Regulatory Officer Nadia Dac - Chief Commercial Officer Steven Whitaker - VP, Clinical Development Conference Call Participants Steve Brozak - WBB Olivia Brayer - Cantor Fitzgerald John Gionco - Needham & Company Brandon Folkes - Rodman & Renshaw Operator Good afternoon, and welcome to today's Earnings Call for Omeros Corporation. At this time, all participants are in listen-only mode.
Neutral
Business Wire
2 weeks ago
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2024, which include: Net loss for the fourth quarter of 2024 was $31.4 million, or $0.54 per share, compared to a net loss of $32.2 million, or $0.56 per share for the third quarter of 2024. For the year ended December 31, 2024, net loss was $156.8 million, or $2.70 per share, compared to a net loss of $117.
Neutral
Benzinga
3 weeks ago
Top Wall Street Forecasters Revamp Omeros Price Expectations Ahead Of Q4 Earnings
Omeros Corporation OMER will release its fourth-quarter financial results after the closing bell on Monday, March 31.
Neutral
Business Wire
3 weeks ago
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2024, on Monday, March 31, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of th.
Neutral
Business Wire
4 weeks ago
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today reported that clinical trial site activation for enrollment is underway for the company's Phase 3 program evaluating zaltenibart in paroxysmal nocturnal hemoglobinuria (PNH). Zaltenibart (OMS906) is Omeros' investigational inhibitor of MASP-3, the key and most proximal activator of the alternative pathway of complement. Zaltenibart inhibits the intravascular hemolysis treated by C5 inhibitors as well as the extravascular hemolysi.
Positive
Seeking Alpha
1 month ago
Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us
Omeros Corporation's stock rebounded after successful data analysis for narsoplimab, showing 68% lower death risk in HSCT-TMA patients compared to historical controls. FDA requested new statistical analysis for narsoplimab's BLA resubmission, which proved successful, leading to a potential approval by late 2025. Financial risks include limited cash runway and potential market constraints due to upcoming generic competition and insurance issues.
Neutral
Business Wire
1 month ago
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced statistical analysis results related to the expanded access program (EAP) for narsoplimab, Omeros' first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a life-threatening complication in both adult and pediatric hematopoietic stem cell transplantation (HSCT). These latest analyses, conducted.
Charts implemented using Lightweight Charts™